Relationship of Periostin and ODI, EQ-5D

Study of Correlation Between Serum Periostin Levels and Oswestry Disability Index and EQ-5D

The intervertebral disc degeneration (IVDD) is a widely recognized musculoskeletal disorder that impose a substantial socioeconomic burden and respresents one of the most important causes of low back pain. IVDD can result from a variety of factors, including aging, obesity, genetic predispositioin, degeneration of of the multifidus and psoas muscles, osteoporosis, inflammation, and oxidative stress.

The IVD consists of a central gelatinous nucleus pulposus (NP), an outer annulus fibrosus (AF), and superior and inferior cartilaginous endplates. The NP and AF produce a water-rich extracellular matrix (ECM), which is essential for normal trunk function.

Dysfunction of the NP and AF, together with excessive metabolic activity of the enplates triggered by various intrinsic and extrinsic stimuli, leads to endplate degeneration and calcification, and ultimately to IVDD. In addition to aging and mechanical overload, increased oxidative stress and pro-inflammatrory cytokine secretion further accelerate the progression of IVDD.

Periostin is an ECM protein which is associated with mechanical stress, inflammation, and aging, and is known to be closely involved in the development and progression of IVDD. Periostin binds to ECM molecule within the IVD and participates in its maintenance and repair; however, excessive ECM turn over drives IVD degeneration and its progression. Periostin influences IVD degeneration through mechanical stress and inflammatory pathways, and serum periostin levels are elevated in patients with severe IVD degeneration. A recent study demonstrated strong corrrelation between serum periostin concentration and the Pfirmann grading system.

The Oswestry disability index is a validated scale that measures functional disability in patients with spinal pain, and the EQ-5D is a breif questionnaire used to assess health related quality of life. Because serum periostin levels reflect the severity of IVDD, periostin may also influence patient's functional disability and quality of life. However, whether serum periostin concentration correlates with functional disability and quality of life has not yet been studied.

Study Overview

• Status: Recruiting
• Conditions: Intervertebral Disc Disease
• Intervention / Treatment: Other: Blood sampling for ELISA

• Study Type: Observational
• Enrollment (Estimated): 38

Contacts and Locations

• Study Contact: Name: JIHEE Hong; Phone Number: 01046794343; Email: swon13@daum.net

Study Locations

• South Korea
  • Daegu, South Korea
    • Recruiting
    • Hong Ji Hee
    • Contact: Sungwon Jung; Email: swon12@daum.net
    • Contact: JIHEE Hong, Professor; Phone Number: 01046794343; Email: swon13@daum.net
  • Daegu
    • Daegu, Daegu, South Korea, 42601
      • Recruiting
      • Ji Hee
      • Contact: J Hee Hong; Phone Number: 01046794343; Email: swon13@daum.net
      • Contact: Email: swon13@hanmail.net

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

low back pain population with disc degeneration confirmed in MRI

Description

Inclusion Criteria:

• lumbar disc herniation
• lumbar spinal canal stenosis
• patients who have MRI
• patients who can fill in the ODI and EQ5D without other's help

Exclusion Criteria:

• allergic disease
• allergic rhinitis
• asthma
• atopic dermatitis
• chronic sinusitis
• history of cancer
• fracture within 6 months
• severe osteoporosis
• knee osteoarthritis
• hip osteoarthrtis
• spinal surgery within 6 months
• myocardiac infarction
• heart failure
• liver cirrhosis
• chronic kidney disease
• rhematoid disease
• systemic lupus erythematosus
• ankylosing spondylitis
• Crohn's disease
• Ulcerative colitis
• systemic steroid user
• acute or chronic infection
• BMI > 30
• uncontrolled hypertension
• uncontrolled diabetes
• recent history of vaccination

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
back pain patient group	Other: Blood sampling for ELISA; blood sampling to detect the level of periostin and cytokine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Identifying the correlation of periostin level and ODI and EQ5D	Day1

Secondary Outcome Measures

Outcome Measure	Time Frame
Identifying the correlation of the periostin level and Cytokine level and Pfirmann grading	Day1

Collaborators and Investigators

• Sponsor: Keimyung University Dongsan Medical Center

Study record dates

Study Major Dates

• Study Start (Actual): June 22, 2026
• Primary Completion (Estimated): February 27, 2027
• Study Completion (Estimated): February 27, 2027

Study Registration Dates

• First Submitted: June 15, 2026
• First Submitted That Met QC Criteria: June 17, 2026
• First Posted (Actual): June 24, 2026

Study Record Updates

• Last Update Posted (Actual): June 29, 2026
• Last Update Submitted That Met QC Criteria: June 24, 2026
• Last Verified: June 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Intervertebral disc disease; Investigative Techniques; Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Immunologic Techniques; Molecular Probe Techniques; Immunoenzyme Techniques; Immunoassay; Immunosorbent Techniques; Immunohistochemistry; Blood Specimen Collection; Enzyme-Linked Immunosorbent Assay
• Other Study ID Numbers: 2026-04-071

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No